| Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas (NCT05182164) | Institut Bergonié | 2022-04-25 |
| A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma (NCT04780464) | European Organisation for Research and Treatment of Cancer - EORTC | 2022-04-11 |
| Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma (NCT04874311) | Institut Bergonié | 2022-03-01 |
| Lurbinectedin + Doxorubicin In Leiomyosarcoma (NCT05099666) | Massachusetts General Hospital | 2022-02-04 |
| Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors (NCT05154630) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-01-14 |
| Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor (NCT05146440) | Grupo Espanol de Investigacion en Sarcomas | 2021-11-23 |
| Camsirubicin + Pegfilgrastim to Determine MTD in ASTS (NCT05043649) | Monopar Therapeutics | 2021-09-22 |
| Combining Epigenetic And Immune Therapy to Beat Cancer. (NCT04705818) | Institut Bergonié | 2021-07-23 |
| Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients (NCT04757337) | UNICANCER | 2021-06-18 |
| Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments. (NCT03838744) | Italian Sarcoma Group | 2020-05-20 |
| Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas (NCT04028063) | University of Colorado, Denver | 2020-01-28 |
| Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma (NCT04204941) | Epizyme, Inc. | 2019-12-19 |
| Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas (NCT03670069) | Fred Hutchinson Cancer Center | 2019-09-30 |
| Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas (NCT03660930) | University of Washington | 2019-04-01 |
| OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients (NCT03698227) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2018-11-12 |
| SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma (NCT03138161) | Sarcoma Oncology Research Center, LLC | 2017-04-13 |
| Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery (NCT03009201) | OHSU Knight Cancer Institute | 2017-03-10 |
| Geriatric Assessmen of Elderly "Unsuited" Patients Receiving Trabectedin in First Line Treatment For Advanced Soft Tissue Sarcomas (STS) (NCT03022448) | GWT-TUD GmbH | 2017-02-02 |
| A Multicenter, Prospective, oBservational Study to assEss the Clinical activitY and Impact on symptOm Burden and patieNts' HRQoL of Treatment With trabecteDin in aSTS in a Real World Setting in Greece (NCT02618122) | Genesis Pharma S.A. | 2015-12-01 |
| A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma (NCT01975519) | Tracon Pharmaceuticals Inc. | 2013-12-10 |